Ratings Philips NV Nyse

Equities

PHG

US5004723038

Market Closed - Nyse Other stock markets 01:30:01 04/05/2024 am IST			5-day change	1st Jan Change
26.82 ^USD	+0.98%		+29.44%	+14.96%

09:45am	Elekta to Buy Philips Healthcare's Treatment Planning Patent Portfolio	MT
02/05	PHILIPS NV : DZ Bank reiterates its Neutral rating	ZD

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

The company's profit outlook over the next few years is a strong asset.

Weaknesses

With an expected P/E ratio at 51.84 and 22.29 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last few months, analysts have been revising downwards their earnings forecast.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	ESG Refinitiv
PHILIPS NV	+14.96%	24.21B	-
THERMO FISHER SCIENTIFIC	+7.84%	218B	B
DANAHER CORPORATION	+7.35%	183B	B-
INTUITIVE SURGICAL, INC.	+13.04%	134B	B-
BOSTON SCIENTIFIC CORPORATION	+26.03%	106B	A-
SIEMENS HEALTHINEERS AG	-1.33%	61.12B	A-
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+4.81%	50.89B	B+
AGILENT TECHNOLOGIES, INC.	+0.30%	40.3B	A
GE HEALTHCARE TECHNOLOGIES INC.	+2.78%	35.53B	-
RESMED, INC.	+26.14%	32.05B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes